

ATTORNEY DOCKET NO. 14028.0292
Application No. 09/383,695

APPENDIX A

Copy of All Pending Claims After Amendment

1. (Previously amended): A method of inhibiting a rejection response in a primate recipient to foreign mammalian donor cells, tissue or organ, comprising the steps of:
 - a) administering to the recipient an anti-CD3-DT immunotoxin, wherein the immunotoxin comprises sFv-DT390, so as to reduce the recipient's T-cell lymphocyte population by at least 80%, as compared to the recipient's T-cell lymphocyte population prior to administration of the immunotoxin; and
 - b) transplanting the donor cells, tissue or organ, into the recipient, such that a rejection response by the recipient to the donor cells, tissue or organ, is inhibited.
2. (Original): The method of claim 1, wherein the donor cells constitute an organ.
3. (Original): The method of claim 1, wherein the donor cells constitute tissue from an organ.
4. (Original): The method of claim 1, wherein the donor cells are allogeneic.
5. (Withdrawn): The method of claim 1, wherein the donor cells are xenogeneic.
6. (Original): The method of claim 1, further comprising administering an immunosuppressant compound to enhance the anti-T cell effects of the immunotoxin.
7. (Withdrawn): The method of claim 6, wherein the immunosuppressant compound is cyclosporin.
8. (Withdrawn): The method of claim 6, wherein the immunosuppressant compound is mycophenolate mofetil.
9. (Original): The method of claim 6, wherein the immunosuppressant compound is deoxyspergualin.
10. (Original): The method of claim 6, wherein the immunosuppressant compound blocks IL-12-induced induction of interferon- γ .

W173631

ATTORNEY DOCKET NO. 14028.0292
Application No. 09/383,695

22. (Previously amended): The method of claim 6, wherein the immunosuppressant is administered beginning from about 0 to 6 hours before the transplanting step.

26. (Previously added): A method of inhibiting a rejection response in a primate recipient, by inducing immune tolerance to foreign mammalian donor cells, tissue or organ, comprising the steps of:

- a) administering to the recipient an anti-CD3-DT immunotoxin, wherein the immunotoxin comprises sFv-DT390, so as to reduce the recipient's T-cell lymphocyte population by at least 80%, as compared to the recipient's T-cell lymphocyte population prior to administration of the immunotoxin;
- b) administering an immunosuppressant compound to enhance the anti-T cell effects of the immunotoxin; and
- c) transplanting the donor cells, tissue or organ, into the recipient, such that a rejection response by the recipient to the donor cells, tissue or organ, is inhibited.

27. (Previously added): The method of claim 23, wherein the immunosuppressant compound is deoxyspergualin.

28. (Previously added): The method of claim 23, wherein the immunosuppressant compound blocks IL-12-induced induction of interferon- γ .

29. (Previously added): The method of claim 23, wherein the immunosuppressant is administered beginning from about 0 to 6 hours before the transplanting step.